The Ultimate Guide To Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Primary trial aims ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis suffer